EBGLYSS^® (Lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis

Almirall S.A. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending the marketing authorization of EBGLYSS for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.